[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
July 2017

Recent Patterns of Prostate-Specific Antigen Testing for Prostate Cancer Screening in the United States

Author Affiliations
  • 1Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia
  • 2Office of the Chief Medical Officer, American Cancer Society, Atlanta, Georgia
JAMA Intern Med. 2017;177(7):1040-1042. doi:10.1001/jamainternmed.2017.0340

Recommendations for prostate-specific antigen (PSA)-based prostate cancer screening have changed considerably in recent years. In 2008, the US Preventive Services Task Force (USPSTF) recommended against PSA-based prostate cancer screening among men 75 years or older, and in 2012, they recommended against PSA testing for men of all ages.1 Other organizations emphasize shared-decision making for men 50 years or older with a long life expectancy.2 As a result of shifting recommendations, PSA screening rates declined from 37.8% in 2010 to 30.8% in 2013 among men 50 years or older, resulting in substantial declines in prostate cancer incidence.3 However, it is not known if PSA testing has continued to decline. The objective of the present study was to examine PSA testing patterns using recently released 2015 National Health Interview Survey (NHIS) data.